Company
Mersana Therapeutics
Mersana Therapeutics has 7 drugs tracked on RxWires: 1 in Phase 3, 1 in Phase 1/2, 5 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Upifitimab rilsodotin | Phase 3 | High Grade Serous Ovarian Cancer |
| upifitamab rilsodotin | Phase 1/2 | Platinum Resistant Ovarian Cancer |
| XMT-1107 | Phase 1 | Neoplasm Metastasis |
| XMT-1522 | Phase 1 | Advanced Breast Cancer |
| XMT-1001 | Phase 1 | Small Cell Lung Cancer |
| XMT-1592 | Phase 1 | Ovarian Cancer |
| XMT-1536 (Upifitamab Rilsodotin) | Phase 1 | Platinum-sensitive Ovarian Cancer (UPGRADE-A) |
Latest
No recent events.
Follow Mersana Therapeutics on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.